Taking people in United StatesPhase 3

Tests atebimetinib with chemotherapy in advanced pancreatic cancer

Tests atebimetinib added to chemotherapy in adults with metastatic pancreatic cancer.

Key facts

Who runs it: Immuneering Corporation
Where: Abilene, Arlington Heights, Atlanta, Austin, Belleville, Blacksburg, Chicago, Cincinnati, Columbia, Duarte, East Brunswick, Eugene, Fairfax, Fairway, Fort Collins, Germantown, Greenville, Huntsville, Las Vegas, Lone Tree, Madison, Maumee, Miami, Nashville, New York, Newark, Omaha, Peoria, Philadelphia, Phoenix, Pinehurst, Port Saint Lucie, Portland, San Antonio, San Diego, Sarasota, Seattle, Sioux Falls, St. Petersburg, Vancouver, Webster, and West Palm Beach, United StatesSee the 47 sitesAlso in 12 other countries, 85 sites
Trial code: NCT07562152
EU 2026-525617-31-00
U1111-1340-7738
Registry title: Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Recruiting
Phase: Phase 3
People taking part: 570 people, planned
Started: 5 Jun 2026
Expected to end: Feb 2029
Type of study: Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested: Atebimetinib
GnP
mGnP
Record updated: 6 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with pancreatic cancer that has spread to other parts of the body and who have not yet had any cancer drug treatment.

Age: 18 years or older
Sex: All sexes can join
Disease stage: Pancreatic adenocarcinoma that has spread (metastatic), diagnosed within 12 weeks before screening, with at least one measurable tumour
Earlier treatment: No earlier treatment of the whole body for pancreatic cancer (first-line treatment only)

Main reasons for not taking part

Cannot swallow pills
Squamous, adenosquamous, neuroendocrine or acinar pancreatic cancer
Cancer that is only locally advanced and has not spread
Brain or spinal cord metastases that cause symptoms, are untreated or are getting worse

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

Must be ≥18 years of age
Must have confirmed diagnosis according to AJCC staging as follows:; Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Participants must be treatment naive as follows:; First-line PDAC participants will have received no previous systemic anti-cancer therapy
Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria
Adequate organ function, hepatic function, coagulation studies and protocol determined clinical laboratory values

Who cannot take part

Inability to swallow oral medications
Participants with only locally advanced disease
Participant has squamous, adenosquamous, neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma
Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases

Where in United States

Also in 12 other countries, 85 sites

Texas Oncology - West TexasAbilene, United StatesContact: Michole LoganTaking people
Illinois Cancer SpecialistsArlington Heights, United StatesContact: Study TeamTaking people
Piedmont Cancer InstituteAtlanta, United StatesContact: Katie AdamsTaking people
Piedmont HealthcareAtlanta, United StatesContact: Study TeamTaking people
Texas Oncology - AustinAustin, United StatesContact: Marian HeavenTaking people
Regional Cancer CareBelleville, United StatesContact: Denise JohnstoneTaking people
Blue Ridge Cancer CareBlacksburg, United StatesContact: Natasha HoltTaking people
City of HopeChicago, United StatesContact: Jalene TangenTaking people
University of Cincinnati Cancer CenterCincinnati, United StatesContact: Study TeamTaking people
Maryland OncologyColumbia, United StatesContact: Corilynn HughesTaking people
Missouri Cancer AssociatesColumbia, United StatesContact: Crystal JohnsonTaking people
City of HopeDuarte, United StatesContact: Jalene TangenTaking people
Astera Cancer CareEast Brunswick, United StatesContact: Study TeamTaking people
Willamette Valley Cancer InstituteEugene, United StatesContact: Jeanne SchafferTaking people
Virginia Cancer SpecialistsFairfax, United StatesContact: Study TeamTaking people
University of Kansas Cancer CenterFairway, United StatesContact: Study TeamTaking people
Poudre Valley Health Care, IncFort Collins, United StatesContact: Study TeamTaking people
West Cancer CenterGermantown, United StatesContact: Robin PattersonTaking people
Prisma HealthGreenville, United StatesContact: Kim WilliamsTaking people
Clearview Cancer InstituteHuntsville, United StatesContact: Lisa ChapuranTaking people
Comprehensive Cancer CentersLas Vegas, United StatesContact: Lindsay KondoTaking people
Rocky Mountain Cancer CentersLone Tree, United StatesContact: Jennifer HegeTaking people
University of Wisconsin Carbone Cancer CenterMadison, United StatesContact: Study TeamTaking people
Taylor Cancer Research CenterMaumee, United StatesContact: Stephanie AmbroseTaking people
Miami Cancer InstituteMiami, United StatesContact: Study TeamTaking people
Sarah Cannon Research InstituteNashville, United StatesContact: Study TeamTaking people
Tennessee OncologyNashville, United StatesContact: Catt PecknoldTaking people
Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Eileen O'Reilly, MDTaking people
NYU Langone HealthNew York, United StatesContact: Study TeamTaking people
Medical Oncology Hematology ConsultantsNewark, United StatesContact: Elizabeth MacWadeTaking people
University of Nebraska Medical CenterOmaha, United StatesContact: Mahdi HassanTaking people
OSF Medical CenterPeoria, United StatesContact: Peyton SwearingenTaking people
Thomas Jefferson UniversityPhiladelphia, United StatesContact: Study TeamTaking people
City of HopePhoenix, United StatesContact: Study TeamTaking people
FirstHealth of the CarolinasPinehurst, United StatesContact: Heather MartinTaking people
Hematology - Oncology Associates of the Treasure CoastPort Saint Lucie, United StatesContact: Christine GerdesTaking people
Oregon Health and Science UniversityPortland, United StatesContact: Study TeamTaking people
Texas Oncology - San AntonioSan Antonio, United StatesContact: Shannon SyringTaking people
University of California San DiegoSan Diego, United StatesContact: Study TeamTaking people
Florida Cancer Specialists - SouthSarasota, United StatesContact: Study TeamTaking people
University of Washington Fred Hutchinson Cancer CenterSeattle, United StatesContact: Study TeamTaking people
Virginia Mason Medical CenterSeattle, United StatesContact: Study TeamTaking people
Avera Cancer Institute- ResearchSioux Falls, United StatesContact: Study CoordinatorTaking people
Florida Cancer Specialists - NorthSt. Petersburg, United StatesContact: Study TeamTaking people
Northwest Cancer SpecialistsVancouver, United StatesContact: Susan PapenfuseTaking people
Texas Oncology - Gulf CoastWebster, United StatesContact: Tara GrayTaking people
Florida Cancer Specialists - EastWest Palm Beach, United StatesContact: Study TeamTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

The 2 groups in the trial

Atebimetinib + mGnPTreatment being tested
Atebimetinib in combination with modified gemcitabine and nab-paclitaxel for first line pancreatic adenocarcinoma
Treatment: Atebimetinib and mGnP
GnPExisting treatment, for comparison
Standard of care gemcitabine and nab-paclitaxel for first line pancreatic adenocarcinoma

Questions to ask the study team

How often do I need to come in, and for how long each time?
Are travel costs paid?
Can I keep my own doctor?
What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record

Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).

Official title

A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)

Plain-language title

Tests atebimetinib with chemotherapy in advanced pancreatic cancerGenerated from the registry record. The registry title is the official one.

AI summary

From the trial's eligibility criteria. Read by machine on 13 November 2026.

Record updated

6 November 2026